New Hampshire New Drug Report

Manufacturer Name	NDC	Name of Prescription Drug	Date of Commercial Availability	WAC	Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Estimated volume of patients who may be prescribed the drug	Breakthrough Therapy Designation	Priority Review	Acquisition Price	Acquisition Date	General Comments
Genmab US, Inc.	82705-0002-01	EPKINLY 4mg/0.8mL Injection	05/31/2023	1268.80	**Marketing Plan** Activities that support the launch of EPKINLY™ (epcoritamab-bysp) include interactions with healthcare professionals, patients, and payers. These activities are designed to raise awareness and understanding of the approved indication, efficacy and safety data contained in the medicine's FDA approved label. Awareness of EPKINLY™ will be raised through educational websites, print and digital media, and the use of sales representatives to educate about the FDA-approved indication. **Pricing Plan** At Genmab, we are driven by patient impact. We positively impact the lives of people with cancer when our transformational science becomes medicine, and our medicines reach the people who need them and help them live better. The price of our medicines reflects the novelty of our science, its impact on patients, and our commitment to bringing that science to patients. The price of EPKINLY™ (epcoritamab-bysp) takes into consideration its transformational potential as the first and only T-cell engaging bispecific antibody treatment administered subcutaneously for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), which is an aggressive disease with limited treatment options.	30,400 - EPKINLY™ (epcoritamab-bysp) is the first-and-only bispecific antibody given by subcutaneous injection and approved to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that didn't respond after 2 or more prior treatments. DLBCL is the most common type of Non-Hodgkin's lymphoma (NHL) worldwide, accounting for approximately 30 percent of all NHL cases and comprising an estimated 30,400 U.S. cases in 2022. Exact information for the EPKINLY™ indicated patient population is not available in the public domain.	N	Y	N/A	N/A	
Genmab US, Inc.	82705-0010-01	EPKINLY 48mg/0.8mL Injection	05/31/2023	15225.56	**Marketing Plan** Activities that support the launch of EPKINLY™ (epcoritamab-bysp) include interactions with healthcare professionals, patients, and payers. These activities are designed to raise awareness and understanding of the approved indication, efficacy and safety data contained in the medicine's FDA approved label. Awareness of EPKINLY™ will be raised through educational websites, print and digital media, and the use of sales representatives to educate about the FDA-approved indication. **Pricing Plan** At Genmab, we are driven by patient impact. We positively impact the lives of people with cancer when our transformational science becomes medicine, and our medicines reach the people who need them and help them live better. The price of our medicines reflects the novelty of our science, its impact on patients, and our commitment to bringing that science to patients. The price of EPKINLY™ (epcoritamab-bysp) takes into consideration its transformational potential as the first and only T-cell engaging bispecific antibody treatment administered subcutaneously for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), which is an aggressive disease with limited treatment options.	30,400 - EPKINLY™ (epcoritamab-bysp) is the first-and-only bispecific antibody given by subcutaneous injection and approved to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that didn't respond after 2 or more prior treatments. DLBCL is the most common type of Non-Hodgkin's lymphoma (NHL) worldwide, accounting for approximately 30 percent of all NHL cases and comprising an estimated 30,400 U.S. cases in 2022. Exact information for the EPKINLY™ indicated patient population is not available in the public domain.	N	Y	N/A	N/A	